The intended audience for this national educational initiative is rheumatologists, OB/GYNs, and other healthcare professionals within the US who prescribe and/or participate in the treatment of patients taking mycophenolate products, including physicians, nurse practitioners, and physician associates who write prescriptions for mycophenolate products and pharmacists who dispense these products and assist in the care of patients taking mycophenolate products.
The goal of this program is to improve the knowledge, competence, and performance of HCPs prescribing mycophenolate treatment for female patients of reproductive potential.
Upon completion of this activity, participants should be able to:
Identify the pregnancy and fetal risks associated with mycophenolate use in female patients of reproductive potential
Educate and counsel female patients of reproductive potential on the need for pregnancy prevention and planning during mycophenolate treatment
Select safe mycophenolate alternatives for female patients who are pregnant or considering pregnancy
Promptly report pregnancies that occur during mycophenolate treatment to the Mycophenolate Pregnancy Registry
Boston University Disclosure
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
Clinical Care Options Disclosure
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Cara D. Dolin, MD, MPH
Assistant Professor of Obstetrics/Gynecology and Reproductive Biology
Division of Maternal-Fetal Medicine
Obstetrics and Gynecology Institute
Cleveland Clinic Lener College of Medicine
Case Western Reserve University School of Medicine
Cara D. Dolin, MD, MPH, has no relevant financial relationships to disclose.
Diana Girnita, MD, PhD
Scientific and Medical Consultant
Assistant Prof Rheumatology (Volunteer)
University Of Cincinnati
CEO & Founder Rheumatologist OnCall
Diana Girnita, MD, PhD: no relevant financial relationships to disclose.
Jennifer L. Simpson, DNP
Adult-Gerontology Doctor of Nursing Practice
Arizona Arthritis and Rheumatology Associates
Jennifer L. Simpson, DNP, has no relevant financial relationships to disclose.
Faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.
The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Center for Continuing Education have no relevant financial relationships with ineligible companies: Michael Burk, BS – Senior Program Manager, Ilana Hardesty, MA – Assistant Director, Operations.
Dr. Monica Crespo-Bosque, Boston University Chobanian & Avedisian School of Medicine’s activity Course Director conducts clinical trials for Biogen.
Dr. Michael York, Boston University Chobanian & Avedisian School of Medicine’s independent auditor, has no relevant financial relationships to disclose.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Instructions for CME and CNE Credit Hours
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1 AMA PRA Category 1 Credit™, nurses are entitled to receive 1 CNE contact hours, all of which is eligible for pharmacology credit, pharmacists are entitled to receive 1 CPE credit hour and physician assistants are entitled to receive 1 AAPA Category 1 CME credit. Statements of credit will be available to print immediately.
The program has been made available online.
The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Boston University Disclaimer
THIS CONTINUING EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Clinical Care Options Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Clinical Care Options, LLC. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Boston University Chobanian & Avedisian School of Medicine designates this Enduring Material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Contact Hours: 1, all of which is eligible for pharmacology credit.
Continuing Pharmacy Education
This activity is approved for 1 CPE credit(s) under the ACPE universal activity number JA0000185-9999-23-013-H01-P. The activity is available for credit claiming through 60 days after completing this enduring activity.
Physician Associate/Physician Assistant Continuing Medical Education
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until November 29, 2024. PAs should only claim credit commensurate with the extent of their participation.